Fujian Cancer Hospital

This study tests whether giving two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy before surgery can help people with locally advanced cervical cancer. The goal is to see if the tumor disappears completely by the time of surgery. About 43 adults aged …

This study is testing whether adding the drug dalpiciclib to standard hormone therapy can help keep early-stage HR+/HER2- breast cancer from returning. About 2000 women with stage II or III breast cancer will receive either a lower dose for 3 years or a higher dose for 2 years. R…

This study tests whether adding a low-dose chemotherapy pill (capecitabine) to standard treatment (dalpiciclib plus hormone therapy) can help people with a certain type of advanced breast cancer (HR+/HER2-) that has spread to organs like the liver or lungs. About 258 adults will …

This study tests a combination of two drugs, Sac-TMT and QL1706, in people with cervical cancer that has come back or spread. The goal is to see if the treatment can shrink tumors and help patients live longer. About 89 women will take part in this early-phase trial.

This study tests whether adding radiotherapy to immunotherapy after surgery can help people with a certain type of advanced lung cancer (stage III N2 non-small cell lung cancer) live longer without the cancer coming back. About 60 adults aged 18 to 75 who have had surgery and hav…

This study tests a new approach for people with rectal cancer that has spread to the liver. It combines short-course radiation, chemotherapy (CAPOX), and a dual-target immunotherapy (QL1706) to see if this mix can stop the cancer from growing. The trial will enroll 42 adults aged…